<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard Rosenquist, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Maniker, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marianna Crowley, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H550476480"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neuraxial anesthesia techniques are used in many settings: as intraoperative anesthetics, for postoperative pain control, in the peripartum period, and in the management of chronic pain. Patients who are candidates for neuraxial anesthesia techniques may be receiving chronic antiplatelet or anticoagulation therapy, may require anticoagulation during or following surgery, or may receive prophylactic medication for venous thromboembolism in the perioperative period. Patients who receive anticoagulant or antiplatelet therapy are at increased risk for hemorrhagic complications of neuraxial techniques, most notably spinal epidural hematoma (SEH).</p><p>This topic discusses the use of neuraxial anesthesia in patients who are receiving medications that interfere with coagulation or platelet function, including the level of risk and the timing of neuraxial procedures relative to the antithrombotic (anticoagulant and antiplatelet) medication. Issues related to neuraxial anesthesia in individuals with impaired hemostasis for reasons other than medications (eg, severe thrombocytopenia) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Neuraxial analgesia and low platelets'</a> and  <a class="medical medical_review" href="/z/d/html/89517.html" rel="external">"Overview of neuraxial anesthesia", section on 'Spinal-epidural hematoma (SEH)'</a>.)</p><p>For the purpose of this topic, neuraxial anesthesia refers to spinal, epidural, or combined spinal-epidural procedures that may be performed for surgical anesthesia or perioperative analgesia. </p><p>Recommendations for interventional spine and pain procedures in patients receiving antiplatelet or anticoagulant medications are discussed separately [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/94151.html" rel="external">"Spinal cord stimulation: Placement and management", section on 'Patient screening'</a>.)</p><p>The recommendations presented here may be applicable to patients having paravertebral blocks, deep plexus blocks, or deep peripheral nerve blocks (ie, in anatomic locations not amenable to the application of pressure to control hemorrhage). However, there is lack of consensus on the magnitude of risk and on which blocks should be avoided in patients who are anticoagulated. (See  <a class="medical medical_review" href="/z/d/html/397.html" rel="external">"Overview of peripheral nerve blocks", section on 'Patients on antithrombotic medication'</a>.)</p><p class="headingAnchor" id="H550476494"><span class="h1">SPINAL EPIDURAL HEMATOMA (SEH)</span><span class="headingEndMark"> — </span>Bleeding is the major complication of antithrombotic therapy. When bleeding occurs in the closed space of the spinal canal, the expanding hematoma can cause pressure on the spinal cord or cauda equina, which in turn may lead to spinal cord ischemia and infarction, with potential for severe neurologic injury or paraplegia. Following neuraxial anesthesia, bleeding is most commonly from vessels in the prominent venous plexus of the epidural space, although it can be in the subdural or subarachnoid spaces. We will refer to this bleeding as spinal epidural hematoma (SEH); the considerations discussed below do not differ for other bleeding locations within the spinal canal.</p><p>Not all SEHs are related to anesthetic or other medical procedures; SEH can occur spontaneously or following other predisposing events such as back surgery [<a href="#rid2">2</a>]. In a retrospective review of all SEHs at a single institution from 1986 to 2001, 7 of the 17 cases were spontaneous; none were related to neuraxial anesthesia [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H703631600"><span class="h2">Incidence and risk factors for SEH after neuraxial anesthesia</span><span class="headingEndMark"> — </span>The incidence of spinal epidural hematoma (SEH) following neuraxial anesthesia is unknown, but likely very low, based on retrospective studies with small numbers of hematomas [<a href="#rid4">4-9</a>]. Risk factors consistently identified include hemostatic abnormalities (eg, drug induced coagulopathy, thrombocytopenia, renal failure, preeclampsia), advanced age, female sex, osteoporosis, spine abnormalities, epidural rather than spinal anesthesia (thought to be due to larger needle gauge with epidural), administration of multiple drugs that affect hemostasis, and difficult neuraxial procedures [<a href="#rid4">4-6,10,11</a>]. Some of these specific risks are discussed in the discussions of individual drugs below. Older adult patients are thought to be at increased risk because of the high incidence of spinal abnormalities (eg, spinal and foraminal stenosis) such that a small volume bleed may lead to spinal cord or cauda equina compression.</p><p>The risk of SEH related to neuraxial anesthesia is greatest when a patient's hemostatic system is abnormal either at the time a needle is placed in the neuraxial space or at the time of removal of a continuous neuraxial catheter. In all patients on medication affecting hemostasis, the timing of neuraxial anesthesia must be coordinated with discontinuation and resumption of antithrombotic medications to minimize the risk of significant bleeding from disrupted epidural blood vessels. The specific medication and the timing of the last dose are critical pieces of information for the anesthesiologist planning neuraxial procedures. Patients receiving more than one medication affecting hemostasis generally should <strong>not</strong> receive neuraxial anesthesia or analgesia. (See <a class="local">'Guidelines for timing of neuraxial anesthesia procedures'</a> below and <a class="local">'Multiple antithrombotic drugs'</a> below.)</p><p>The incidence of SEH after neuraxial anesthesia among obstetric patients appears to be lower than in non-obstetric patients, based on retrospective database and literature reviews [<a href="#rid8">8,10</a>]. </p><p>Examples of studies of incidence of SEH include the following, although these may not reflect the true incidence due to under-reporting:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 2004 retrospective study of neuraxial anesthetics over a decade in Sweden, 25 SEHs occurred after approximately 450,000 epidural anesthetics (1:18,000), and eight occurred after 1,260,000 spinal anesthetics (1:158,000) [<a href="#rid4">4</a>]. The incidence of hemorrhagic complications varied significantly depending on the population, from 1 in 200,000 for obstetric patients to 1 in 3600 for female knee arthroplasty patients who received epidural or combined spinal-epidural anesthesia. Of the 33 hematomas, 11 (33 percent) were in patients with coagulopathy or who had an antithrombotic drug administered in temporal proximity to the block, 10 (30 percent) had difficult placement, and 6 (18 percent) had spine pathology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2013 review of outcomes of epidural catheterization from the Multicenter Perioperative Outcomes Group, SEH requiring laminectomy for SEH evacuation occurred in 7 out of 62, 450 (1:8900) surgical patients, and in none of 79,837 obstetric patients [<a href="#rid5">5</a>]. Four patients who developed SEH had received anticoagulant or antiplatelet medications in a way that deviated from the existing American Society of Regional Anesthesia and Pain Medicine (ASRA) guidelines, two had difficult neuraxial placement, and one patient was undergoing dialysis and thus may have been at increased risk because of platelet dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single center retrospective database review of SEH after surgical or obstetric epidural catheterization from 2001 to 2009, SEH occurred in 6 of 43,200 patients (1:7200), none of whom were obstetric patients [<a href="#rid10">10</a>]. All patients with SEH were over the age of 70, and all received perioperative anticoagulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are a number of case reports of SEH in obstetric patients who were coagulopathic at the time of epidural catheter placement or removal [<a href="#rid4">4,12,13</a>]. However, a systematic review of the literature from 1952 to 2016 found no cases of SEH after neuraxial anesthesia in obstetric patients that were thought to be related to thromboprophylaxis [<a href="#rid8">8</a>]. </p><p></p><p class="headingAnchor" id="H523716815"><span class="h2">Typical presentation</span><span class="headingEndMark"> — </span>SEH is not clinically apparent until pain or neurologic deficits appear. The most common presenting symptoms of a neurologically-significant SEH are a progressive motor and sensory block (68 percent of patients) or bowel/bladder dysfunction (8 percent); unlike classical disc herniation, radicular pain is an uncommon presenting symptom in patients with SEH [<a href="#rid14">14</a>]. In the American Society of Anesthesiologists (ASA) Closed Claims analysis, 83 percent of patients with SEH presented with increased motor block, and 25 percent with back pain [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H703630940"><span class="h1">DECISION TO USE NEURAXIAL ANESTHESIA IN PATIENTS ON ANTITHROMBOTIC MEDICATION</span><span class="headingEndMark"> — </span>The decision to use neuraxial anesthesia in patients who either have been or will be receiving antithrombotic medication must weigh the benefit of the neuraxial anesthetic against the risk of spinal epidural hematoma (SEH).</p><p class="headingAnchor" id="H1658107711"><span class="h2">Surgical versus obstetric patients</span><span class="headingEndMark"> — </span>The decision to use neuraxial anesthesia techniques in patients who receive antithrombotic therapy is somewhat different between surgical and obstetric patients. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical patients</strong> – Surgical patients on chronic antithrombotic medication usually have the medication discontinued, medication changed (eg, bridging), or dosing modified prior to elective procedures to minimize surgical bleeding; if antithrombotic medication must be continued without interruption, or for urgent procedures in patients who have received such medications, neuraxial anesthesia may not be an option.</p><p></p><p class="bulletIndent1">Generally, the decision regarding whether or not to continue the anticoagulant up to the time of the procedure is made by weighing the risk of thrombosis if the anticoagulant is stopped versus the bleeding risk of the procedure, as discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Deciding whether to interrupt anticoagulation'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obstetric patients </strong>– Decisions regarding the use of neuraxial anesthesia or analgesia in obstetric patients who receive antithrombotic medications are more complex. The small risk of SEH must always be balanced against the patient specific risks of general anesthesia, which may be higher in obstetric patients  (<a class="graphic graphic_algorithm graphicRef118088" href="/z/d/graphic/118088.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef118090" href="/z/d/graphic/118090.html" rel="external">algorithm 2</a>) [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/4480.html" rel="external">"Anesthesia for cesarean delivery", section on 'General versus neuraxial anesthesia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The need for obstetric neuraxial analgesia or anesthesia is often unpredictable, and delay of neuraxial techniques to allow an appropriate interval from last administration of an antithrombotic medication may be undesirable or harmful. For patients who receive antithrombotic therapy during pregnancy, it may be beneficial to switch from low molecular weight heparin (LMWH) to <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH), or to reduce the antenatal dose of UFH, near the end of pregnancy (eg, at approximately 36 weeks) to facilitate neuraxial procedures [<a href="#rid16">16</a>]. (See <a class="local">'Unfractionated heparin (UFH)'</a> below and <a class="local">'Low molecular weight heparin (LMWH)'</a> below and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum", section on 'Labor and delivery'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neuraxial anesthesia is the technique of choice for cesarean delivery and for labor analgesia; general anesthesia for cesarean delivery is associated with increased intraoperative and postoperative adverse events for both mother and fetus compared with neuraxial anesthesia. Neuraxial labor analgesia may be initiated early in labor specifically to reduce the need for general anesthesia for an unplanned cesarean delivery in select patients (eg, patients with severe preeclampsia or predicted difficult airway). (See  <a class="medical medical_review" href="/z/d/html/4480.html" rel="external">"Anesthesia for cesarean delivery", section on 'General versus neuraxial anesthesia'</a> and  <a class="medical medical_review" href="/z/d/html/101803.html" rel="external">"Neuraxial analgesia for labor and delivery (including instrumental delivery)", section on 'Preparation for surgical anesthesia'</a>.)</p><p></p><p class="headingAnchor" id="H3132119962"><span class="h1">SPINAL VERSUS EPIDURAL TECHNIQUE</span><span class="headingEndMark"> — </span>When neuraxial anesthesia is used in patients on antithrombotic medication, use of a single-shot spinal technique rather than an epidural may decrease the risk of spinal epidural hematoma (SEH), as estimates of risk are greater with larger needles (epidural compared with spinal) and in techniques with continuous catheters (continuous epidural or continuous spinal) [<a href="#rid4">4</a>]. (See <a class="local">'Incidence and risk factors for SEH after neuraxial anesthesia'</a> above.)</p><p class="headingAnchor" id="H1882507772"><span class="h1">MULTIPLE ANTITHROMBOTIC DRUGS</span><span class="headingEndMark"> — </span>We agree with recommendations from the American Society of Regional Anesthesia and Pain Medicine (ASRA) that neuraxial techniques should <strong>not</strong> be performed in patients who receive more than one antithrombotic medication simultaneously [<a href="#rid17">17</a>]. </p><p>This includes any combination of anticoagulants such as <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH), low molecular weight heparin (LMWH), <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, a direct oral anticoagulant, and/or antiplatelet agents, such as a nonsteroidal antiinflammatory drug (NSAID; including <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, but not COX-2 inhibitors), a P2Y<sub>12</sub> receptor blocker, or <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a>. </p><p>For patients with indwelling epidural catheters, the patient's medical record should be reviewed daily for all medications that affect hemostasis. The decision to maintain an epidural catheter in patients who receive anticoagulant or antiplatelet medication (including combinations of such medications) should always involve a risk/benefit analysis. In some cases, the epidural catheter should be removed prior to administration of a second medication that affects hemostasis.  </p><p>As an example, although a spinal or epidural technique may be performed in a patient who has received <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> as the sole antithrombotic medication up until the day of the procedure, an epidural catheter should not be maintained postoperatively if that same patient receives LMWH or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> after surgery, while the aspirin effect is still present (typically considered to be approximately five to seven days since the last dose of aspirin) (see <a class="local">'LMWH thromboprophylaxis'</a> below and <a class="local">'Postoperative initiation of warfarin'</a> below). Similarly, neuraxial anesthesia should not be performed in patients who have taken aspirin up to the day of the procedure if they will receive intraoperative intravenous heparin.</p><p>The risk of spinal epidural hematoma (SEH) in patients who receive low dose subcutaneous heparin (ie, 5000 units subcutaneously two to three times daily) along with antiplatelet medication is unknown, but likely increased. Whereas SEH has not been reported in patients who have received low dose thromboprophylaxis with UFH along with antiplatelet medication, administration of multiple anticoagulant medications is a known risk factor for SEH in patients who receive higher dose UFH. (See <a class="local">'Incidence and risk factors for SEH after neuraxial anesthesia'</a> above.)</p><p>Avoidance of neuraxial anesthesia in patients who have taken more than one medication that affects hemostasis is based on the following types of indirect evidence: </p><p class="bulletIndent1"><span class="glyph">●</span>Increased bleeding from other sites has been reported with combination antithrombotic therapy [<a href="#rid18">18</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Case series of patients with SEH have included many patients receiving more than one antithrombotic medication [<a href="#rid14">14,15,19,20</a>]. </p><p></p><p class="headingAnchor" id="H703631051"><span class="h1">GUIDELINES FOR TIMING OF NEURAXIAL ANESTHESIA PROCEDURES</span></p><p class="headingAnchor" id="H2881804018"><span class="h2">Overview of timing of neuraxial anesthesia</span><span class="headingEndMark"> — </span>Guidelines have been developed for the timing of neuraxial procedures and removal of neuraxial catheters relative to administration of antithrombotic medications, and timing of administration of antithrombotic medications after such procedures, to minimize the risk of hemorrhage [<a href="#rid16">16,17,21,22</a>]. The guidelines represent a consensus of expert opinion, and are often based on case reports, case series, and knowledge of the pharmacokinetics, pharmacodynamics, and actions of each drug. Thus, the specific recommendations in these guidelines may vary somewhat  (<a class="graphic graphic_table graphicRef87862" href="/z/d/graphic/87862.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef138528" href="/z/d/graphic/138528.html" rel="external">table 2</a>). </p><p>For newer drugs for which there is less clinical experience, recommendations are often based on elimination half-lives. Some experts and organizations recommend an interval of two drug half-lives between the last dose and performance of neuraxial anesthesia, particularly for patients with a high risk of thrombosis. This strategy would mean that a low level of anticoagulation may be present when neuraxial anesthesia is performed. A more conservative approach would be to wait for five elimination half-lives, which would result in approximately 97 percent elimination; such a strategy may be more appropriate for patients with a low risk of thrombosis. Management decisions should ultimately be individualized based on the patient specific risks of bleeding versus thrombosis.</p><p>Unless noted, our recommendations are consistent with the 2018 American Society of Regional Anesthesia and Pain Medicine (ASRA) guidelines for the use of regional anesthesia in patients on various antithrombotic and thrombolytic medications [<a href="#rid17">17</a>], which are shown in a table  (<a class="graphic graphic_table graphicRef87862" href="/z/d/graphic/87862.html" rel="external">table 1</a>). </p><p>Guidelines have also been published by anesthesiology societies in Europe  (<a class="graphic graphic_table graphicRef138528" href="/z/d/graphic/138528.html" rel="external">table 2</a>) [<a href="#rid21">21-25</a>] as well as the US Food and Drug Administration (FDA) for specific drugs. (See <a class="local">'Society guideline links'</a> below.)</p><p>Significant differences between the ASRA recommendations and those of other organizations are noted in the text below, and in the table  (<a class="graphic graphic_table graphicRef87862" href="/z/d/graphic/87862.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H171345729"><span class="h1">UNFRACTIONATED HEPARIN (UFH)</span><span class="headingEndMark"> — </span>The effect of UFH can be monitored with the activated partial thromboplastin time (aPTT) or by anti-factor Xa activity. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Monitoring heparins'</a>.)</p><p>If necessary, UFH can be reversed with protamine. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Unfractionated heparin'</a>.)</p><p>Due to the risk of heparin-induced thrombocytopenia (HIT) for patients who have received intravenous (IV) or subcutaneous UFH heparin for four or more days, platelet count should be checked prior to performing neuraxial anesthesia and/or prior to neuraxial catheter removal. In addition, periodic platelet count monitoring may be appropriate, depending on the baseline risk of HIT, as discussed separately (see  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Platelet count monitoring'</a>). HIT may occur in 0.1 to 5 percent of surgical patients who are exposed to UFH for more than 4 days; the risk in obstetric patients is approximately 0.1 to 1 percent. American Society of Regional Anesthesia and Pain Medicine (ASRA) recommends checking a platelet count for patients who have received heparin for more than four days  (<a class="graphic graphic_table graphicRef87862" href="/z/d/graphic/87862.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H703631065"><span class="h2">Intravenous UFH</span><span class="headingEndMark"> — </span>Anticoagulation with IV heparin may be required at any point in the perioperative period, including after performance of neuraxial procedures, and with epidural catheters in place. Risk factors for spinal epidural hematoma (SEH) during heparin therapy include traumatic needle placement, coagulation disorders, concomitant administration of other drugs that affect hemostasis, and administration of heparin less than one hour after neuraxial needle placement [<a href="#rid19">19,20</a>]. </p><p>The anticoagulant effect of IV heparin is immediate. Metabolism of heparin is complex and dose dependent, with a half-life of approximately 45 minutes to one hour [<a href="#rid26">26,27</a>]. When heparin is stopped preoperatively, the effect is expected to be largely eliminated after five half-lives (approximately four to five hours). (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Elective procedure/minor bleeding'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative IV UFH </strong>–<strong> </strong>Neuraxial anesthesia techniques may be used in patients who have been receiving therapeutic anticoagulation with IV UFH (aPTT &gt;1.5 to 2 times baseline level), if the heparin can be temporarily discontinued, and it is clinically acceptable to return to normal coagulation status for several hours both for epidural or spinal insertion, and for removal of a continuous catheter. Heparin infusion should be stopped for at least 4 to 6 hours and a normal aPTT should be documented prior to neuraxial anesthesia or catheter removal [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV UFH bolus during surgery </strong>– IV UFH should not be administered for at least one hour after a neuraxial anesthesia procedure or neuraxial catheter removal. Vascular surgery often requires IV administration of UFH (typically 5000 to 10,000 units) prior to clamping large vessels. There is extensive experience with the safe use of therapeutic intraoperative UFH in patients with epidural catheters, when the heparin was given at least one hour after the neuraxial catheter placement [<a href="#rid29">29</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative IV UFH – </strong>When epidural analgesia is used in conjunction with IV UFH, use of the smallest effective concentrations of local anesthetic will allow for earlier recognition, imaging, and management should motor or sensory loss be caused by SEH. (See <a class="local">'Prevention of neurologic damage from spinal hematoma'</a> below.)</p><p></p><p class="bulletIndent1">The epidural catheter should be removed four to six hours after the last dose of IV UFH and after a normal aPTT is documented. IV UFH should not be administered for at least one hour after removal of an epidural catheter. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Traumatic neuraxial needle or catheter placement </strong>– After a traumatic (bloody) neuraxial procedure, therapeutic heparinization probably increases the risk of SEH compared with the use of lower dose prophylactic heparin, although the magnitude of risk is unknown [<a href="#rid28">28</a>]. Intraoperative heparinization is mandatory for some surgical procedures. When neuraxial needle or catheter placement is traumatic (bloody) or requires multiple attempts, concerns about subsequent anticoagulation should be discussed with the surgeon, including the possibility of delaying the case for 24 hours. In the case of an urgent surgical procedure that requires heparinization, sensory and motor neurologic function should be closely monitored around the time of expected recovery from anesthesia. Using the lowest effective concentrations of local anesthetic in the postoperative period facilitates monitoring of motor blockade and earlier detection of SEH. (See <a class="local">'Neurologic monitoring'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiopulmonary bypass </strong>–<strong> </strong>The use of neuraxial techniques for postoperative analgesia (eg, epidural analgesia or neuraxial opioids) for cardiac surgery that requires cardiopulmonary bypass is controversial. Higher dose IV UFH is required for these procedures, compared with other surgery, which may increase the risk of SEH. Spontaneous SEH has been reported after heparinization for cardiopulmonary bypass [<a href="#rid30">30</a>], but SEH related to neuraxial anesthesia in these patients has not been reported, and the incidence of this complication is unknown [<a href="#rid31">31-33</a>]. </p><p></p><p class="headingAnchor" id="H87655635"><span class="h2">Subcutaneous UFH</span><span class="headingEndMark"> — </span>The effect of prophylactic dose subcutaneous <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) on the aPTT (and therefore the risk of bleeding) is variable. The onset of effect of subcutaneous heparin occurs in 20 to 30 minutes and peaks at two to four hours, with considerable individual variation [<a href="#rid27">27</a>]. Subcutaneous heparin is administered two or three times per day. Up to 7 percent of patients develop an aPTT &gt;1.5 times the normal level, especially those who are frail and/or older adults, and small number of patients become fully anticoagulated after a dose of 5000 units subcutaneously [<a href="#rid34">34,35</a>]. </p><p>Recommendations for the timing of neuraxial procedures and catheter removal depend on the dose of subcutaneous UFH administered. Higher doses are often used for pregnant patients. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low dose thromboprophylaxis (5000 units subcutaneously two or three times daily) </strong>– Neuraxial anesthesia techniques or catheter removal should be performed at least four to six hours after the last dose, or after confirmation of normal aPTT or anti-factor Xa level prior to the procedure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher dose thromboprophylaxis (7500 to 10,000 units subcutaneously twice daily, total daily dose ≤20,000 units)</strong> – Neuraxial anesthesia or catheter removal should be performed at least 12 hours after last dose and after confirmation of normal aPTT or anti-factor Xa level.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutic dose UFH (individual dose &gt;10,000 units subcutaneously or total daily dose &gt;20,000 units) </strong>–<strong> </strong>Neuraxial anesthesia or catheter removal should be performed at least 24 hours after last dose and after confirmation of a normal aPTT or anti-factor Xa level.</p><p></p><p>Low dose (5000 units) subcutaneous UFH may be administered immediately after performance of a neuraxial procedure or removal of a neuraxial catheter. </p><p class="headingAnchor" id="H703631072"><span class="h1">LOW MOLECULAR WEIGHT HEPARIN (LMWH)</span><span class="headingEndMark"> — </span>Low molecular weight heparin (LMWH) is increasingly used rather than <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) for thromboprophylaxis and for therapeutic anticoagulation. Compared with UFH, LMWHs have longer half-lives, are associated with a lower incidence of heparin-induced thrombocytopenia (HIT), cannot be fully reversed with protamine, and cannot be assessed with an aPTT [<a href="#rid36">36</a>]. Anti-factor Xa levels where available can be measured to assess LMWH effect, but safe levels for performance of neuraxial anesthesia have <strong>not</strong> been determined. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'LMW heparin'</a>.)</p><p>A number of cases of spinal epidural hematoma (SEH) have been reported in patients who had neuraxial anesthesia while receiving LMWH at various doses. The labels of all anticoagulants, including LMWHs, include a boxed warning from the US Food and Drug Administration (FDA) regarding this risk. In addition, in 2016 the FDA issued a safety warning for the timing of neuraxial anesthesia in patients receiving LMWHs to decrease the risk of bleeding [<a href="#rid37">37</a>]. The recommendations were prompted by report of 100 confirmed spinal hematomas between 1992 and 2013 in patients who had spinal or epidural anesthesia and were receiving prophylactic dose <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>. Twice daily dosing of enoxaparin was identified among half of the reported cases. (See <a class="local">'Incidence and risk factors for SEH after neuraxial anesthesia'</a> above.)</p><p>The available LMWHs differ with respect to their chemical properties, doses, and half-lives. Thus, recommendations for the timing of neuraxial anesthesia are based on the specific drug, dose, and frequency of administration. Perioperative bridging anticoagulation with LMWH may be prescribed at prophylactic, intermediate, or therapeutic dosing levels. (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Heparin product and dose'</a>.) </p><p>The risk of HIT is lower with LMWH than with <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a>. HIT occurs in 0.1 to 1 percent of postoperative patients who receive thromboprophylaxis with LMWH, whereas medical or obstetric patients who receive LMWH have a risk of HIT of &lt;0.1 percent. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Platelet count monitoring'</a>.)</p><p>To evaluate for HIT, a platelet count should be checked prior to neuraxial anesthesia in patients who have received LMWH for four or more days. In addition, subsequent periodic platelet count monitoring may be appropriate, depending on the baseline risk of HIT, as discussed separately (see  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Platelet count monitoring'</a>). Similarly, American Society of Regional Anesthesia and Pain Medicine (ASRA) recommends checking a platelet count for patients who have received LMWH for more than four days. However, practice varies, and other organizations make different recommendations because of the low risk of HIT with LMWH. As an example, the 2017 Society for Obstetric Anesthesia and Perinatology consensus statement on anesthesia for patients who receive anticoagulants does not recommend routine platelet count monitoring for obstetric patients who receive LMWH [<a href="#rid16">16</a>]. The American College of Chest Physicians (ACCP) Practice Guidelines do not recommend routine platelet count monitoring for patients with a risk of HIT &lt;1 percent. Criteria for evaluating the likelihood of HIT and platelet count thresholds for neuraxial anesthesia are discussed in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a> and  <a class="medical medical_review" href="/z/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Neuraxial analgesia and low platelets'</a> and  <a class="medical medical_review" href="/z/d/html/94369.html" rel="external">"Anesthesia for the patient with preeclampsia", section on 'Coagulation'</a>.)</p><p>LMWHs are cleared by the kidneys, and the FDA recommends doubling the intervals between LMWH dosing and neuraxial procedures, and between neuraxial procedures and subsequent dosing, for patients with creatinine clearance (CrCl) &lt;30 mL per minute.</p><p>When neuraxial needle or catheter placement is traumatic (bloody) or requires multiple attempts, LMWH may be dosed no sooner than 24 hours after the placement or attempt, and these concerns should be discussed with the surgeon. </p><p class="headingAnchor" id="H87655321"><span class="h2">Therapeutic LMWH</span><span class="headingEndMark"> — </span>Patients who are receiving therapeutic doses of low molecular weight heparin (LMWH) are at greater risk of SEH with neuraxial needle or catheter placement than those treated with prophylactic doses. Additional caution is required in patients on long-term LMWH and in patients with renal failure, which may lead to accumulation of anticoagulant effect and fibrinolysis [<a href="#rid38">38</a>]. </p><p>Therapeutic doses of LMWH include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">Enoxaparin</a> (Lovenox) 1 mg/kg every 12 hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">Enoxaparin</a> 1.5 mg/kg daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">Dalteparin</a> (Fragmin) 100 to 120 units/kg every 12 hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">Dalteparin</a> 200 units/kg daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">Tinzaparin</a> (Innohep, Logiparin) 175 units/kg daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10060" href="/z/d/drug information/10060.html" rel="external">Nadroparin</a> (Fraxiparine) 86 units/kg every 12 hours </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10060" href="/z/d/drug information/10060.html" rel="external">Nadroparin</a> 171 units/kg daily</p><p></p><p class="bulletIndent1">ASRA guidelines recommend performing a neuraxial anesthetic no sooner than 24 hours after the last dose of LMWH (therapeutic) [<a href="#rid17">17</a>]. Guidelines from the European Society of Anesthesiology and Intensive Care/European Society of Regional Anesthesia (ESAIC/ESRA) also recommend an interval of 24 hours between the last dose of high dose LMWH, except in patients with CrCl &lt; 30 mL/min, for whom they recommend waiting 48 hours or until the anti-factor Xa activity is ≤ 0.1 IU/mL [<a href="#rid22">22</a>].</p><p></p><p>The first postoperative dose of therapeutic dose LMWH should not be administered until at least four hours after neuraxial catheter removal and a minimum of 24 hours after the initial needle/catheter placement. Neuraxial catheters should be removed prior to initiation of therapeutic dosing.</p><p class="headingAnchor" id="H87655733"><span class="h2">LMWH thromboprophylaxis</span><span class="headingEndMark"> — </span>Many surgical patients receive LMWH for thromboembolism prophylaxis. Neuraxial anesthesia (including continuous catheters) may be used in these patients if they are not receiving any other medications that affect hemostasis. Recommendations are summarized in the table  (<a class="graphic graphic_table graphicRef87862" href="/z/d/graphic/87862.html" rel="external">table 1</a>).</p><p>Prophylactic doses include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">Enoxaparin</a> 30 mg every 12 hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">Enoxaparin</a> 40 mg daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">Dalteparin</a> 2500 to 5000 units daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10060" href="/z/d/drug information/10060.html" rel="external">Nadroparin</a> 2850 units daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10060" href="/z/d/drug information/10060.html" rel="external">Nadroparin</a> 38 units/kg daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">Tinzaparin</a> 50 to 75 units/kg daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">Tinzaparin</a> 3500 units daily</p><p></p><p>A neuraxial anesthetic may be inserted at least 12 hours after the last dose of LMWH (prophylactic). Postoperative twice daily dosing of <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> is associated with an increased risk of SEH [<a href="#rid17">17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Twice daily prophylactic LMWH </strong>– ASRA guidelines recommend removing the epidural catheter prior to initiation of twice daily prophylactic LMWH heparin therapy (<a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> 30 mg twice daily). The first postoperative dose should be administered no earlier than 12 hours after neuraxial procedure and at least four hours after catheter removal [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1">The European Society of Anesthesiology (ESA) guidelines allow for maintenance of an epidural catheter during twice daily prophylactic dosing, but, prior to catheter removal, one scheduled dose should be omitted, and the catheter removed 24 hours after the last dose [<a href="#rid39">39</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Once per day prophylactic LMWH</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For a single injection neuraxial procedure, the first postoperative dose of LMWH should be administered no earlier than 12 hours after the neuraxial procedure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Indwelling neuraxial catheters may be maintained during once daily prophylaxis as long as no other drugs that affect hemostasis are administered. For neuraxial catheters, the first postoperative dose of LMWH should be administered at least 12 hours after the neuraxial procedure, and the second dose should be administered no sooner than 24 hours after the first. The catheter should be removed at least 12 hours after the last dose of LMWH, and the subsequent dose should be administered at least four hours after catheter removal.</p><p></p><p class="headingAnchor" id="H1880583036"><span class="h1">WARFARIN</span></p><p class="headingAnchor" id="H1714381999"><span class="h2">General issues</span><span class="headingEndMark"> — </span>The mechanism of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> action differs from other anticoagulants, both at the time of anticoagulant discontinuation and initiation, when effects on clotting factors may not be accurately reflected in the prothrombin time/international normalized ratio (PT/INR). The response to an initial dose of warfarin depends on the dose and patient factors that may increase sensitivity (eg, female sex, advanced age, frailty, liver or kidney disease, dietary <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> deficiency, and certain medications). The biology of warfarin and its effect on clotting factors during discontinuation and initiation of therapy are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Initial dosing'</a>.)</p><p>The INR is not specifically validated for documenting normal coagulation status, and the "normal range" for the INR is not well-defined. Some individuals have a baseline INR slightly above 1 (range 1.2 to 1.3). In an individual who has been taking <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, an INR of 1.3 may represent that individual's baseline INR, or it may signify that their coagulation status has not returned to normal. This variation is reflected in the various INR cutoffs for neuraxial anesthesia used by different societies (eg, "normal," INR is used in the American Society of Regional Anesthesia and Pain Medicine (ASRA) and European Society of Anesthesiology and Intensive Care/European Society of Regional Anesthesia (ESAIC/ESRA) guidelines, and INR &lt;1.4 is used in the British guidelines) [<a href="#rid17">17,21</a>]. In practical terms, the cutoff used to allow neuraxial anesthesia should be based on institutional guidelines, laboratory normal ranges, and the judgment of the individual performing the procedure. This subject is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7920.html" rel="external">"Clinical use of plasma components", section on 'Settings in which plasma is not appropriate'</a>.) </p><p class="headingAnchor" id="H4051693490"><span class="h2">Preoperative warfarin discontinuation</span><span class="headingEndMark"> — </span>For individuals receiving <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> preoperatively, the drug needs to be discontinued with sufficient time to allow coagulation status to return to normal before performing neuraxial anesthesia. In rare cases (eg, for urgent or emergency surgery), a reversal agent such as <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> or a prothrombin complex concentrate (PCC) may be used (see  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Warfarin interruption'</a>). Recommendations from anesthesia societies regarding neuraxial anesthesia in patients who have received or will receive warfarin vary in significant ways, as discussed below. </p><p>Spinal or epidural anesthesia or analgesia may be used in patients who have discontinued <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, ideally at least five days earlier (ie, last dose is given on day minus 6), or who have had warfarin reversed, if coagulation status is normal as indicated by a PT within (or below) the normal range for the testing laboratory, or INR ≤ 1.2, at the time of neuraxial needle or catheter insertion. (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Warfarin interruption'</a>.) </p><p class="headingAnchor" id="H1080791049"><span class="h2">Postoperative initiation of warfarin</span><span class="headingEndMark"> — </span>The use of neuraxial techniques in patients who receive <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> for postoperative thromboprophylaxis is controversial. The anesthesia societies disagree on the performance of neuraxial anesthesia techniques, and on the use of epidural catheters postoperatively, in patients who receive warfarin for postoperative thromboprophylaxis. ASRA guidelines allow for performance of neuraxial anesthesia techniques within 24 hours after a single dose of warfarin and for maintenance of neuraxial catheters during initiation of postoperative warfarin thromboprophylaxis [<a href="#rid17">17</a>], whereas the ESA [<a href="#rid39">39</a>] and British guidelines [<a href="#rid21">21</a>] recommend removing an epidural catheter prior to administration of postoperative warfarin.</p><p><a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a> was widely used for postoperative thromboprophylaxis before the advent of LMWH and direct oral anticoagulants for this purpose. There are two case reports of spinal epidural hematoma (SEH) in patients who had epidural catheters removed during full postoperative anticoagulation with warfarin, one with an INR over 6 [<a href="#rid40">40</a>], and another who had the catheter removed after four days of warfarin with a PT of 17.3 (normal range 11.2 to 14.4) [<a href="#rid41">41</a>]. There are several large observational studies on the concomitant use of postoperative epidural analgesia with initiation of warfarin. While they provide some measure of reassurance that epidural analgesia may be used safely during early initiation of warfarin therapy, much larger studies would be required to draw definitive conclusions, given the rarity of SEH. </p><p class="bulletIndent1"><span class="glyph">●</span>In a multi-institutional study including 4365 patients who underwent total hip or knee arthroplasty with postoperative epidural analgesia and thromboprophylaxis with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, and in all cases with removal of the epidural catheter with an INR &gt;1.4, there were no cases of SEH [<a href="#rid42">42</a>]. The only antithrombotic medication in effect at the time of surgery was a nonsteroidal antiinflammatory drug (NSAID) in some patients. In all patients, the first warfarin dose was administered on the night of surgery, at a dose that varied with the individual institutional protocol. Most catheters were removed on postoperative day 2 (4090 patients). Mean INR at the time of catheter removal was 1.9, with a range of 1.5 to 5.9. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single institution retrospective database review of records from approximately 13,000 patients who underwent total hip or knee arthroplasty with epidural analgesia and postoperative <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, there were no cases of SEH [<a href="#rid43">43</a>]. The first dose of warfarin was administered the night of surgery. The epidural catheter was removed within 48 hours of surgery unless the INR was &gt;2, in which case removal was delayed. Among 1038 case records that were reviewed in detail, the mean INR at the time of catheter removal was 1.54 (range 0.93 to 4.25). </p><p></p><p>We agree with the ASRA recommendations regarding the management of neuraxial catheters during administration of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> for postoperative thromboprophylaxis, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The epidural catheter should be removed prior to administration of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> in patients who have received any other medication that affects hemostasis, including <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or other NSAIDs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spinal or epidural anesthesia and analgesia may be initiated or an epidural catheter may be removed without documentation of a normal PT or INR when a single <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> dose was given &lt;24 hours earlier, before an anticoagulant effect has occurred. If a second dose has been given, or &gt;24 hours have elapsed since the dose, a normal PT or INR should be documented prior to placing a neuraxial needle or catheter. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Initial dosing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The PT/INR should be checked daily in individuals receiving <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> who have a neuraxial catheter in place.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An epidural catheter kept in place beyond 24 hours after a dose of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> should be removed only when the INR is &lt;1.5. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ASRA makes no recommendation regarding catheter removal in patients with INR between 1.5 and 3. We remove epidural catheters in these patients as long as other drugs affecting hemostasis were not used in combination with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, and perform neurologic monitoring for 24 to 48 hours after catheter removal, or until the INR has stabilized at the desired level.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with an INR &gt;3 (likely supratherapeutic), we recommend holding or reducing the <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> dose in patients with indwelling epidural catheters, and delaying catheter removal until the INR is &lt;3. Management of patients with a supratherapeutic INR is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sensory and motor function should be monitored closely during epidural analgesia for patients receiving <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, and for 24 hours after catheter removal. We suggest using the lowest effective concentration of local anesthetic to facilitate evaluation of sensory and motor neurologic function. (See <a class="local">'Neurologic monitoring'</a> below.)</p><p></p><p class="headingAnchor" id="H1195587532"><span class="h1">DIRECT ORAL ANTICOAGULANTS (DOACS)</span><span class="headingEndMark"> — </span>DOACs include oral direct factor Xa inhibitors and the direct thrombin inhibitor <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>.  (<a class="graphic graphic_figure graphicRef94856" href="/z/d/graphic/94856.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H1335891"><span class="h2">Direct oral factor Xa inhibitors</span><span class="headingEndMark"> — </span>There is limited experience with direct oral factor Xa inhibitors and neuraxial anesthesia. Spinal epidural hematoma (SEH) has been reported with the use of these agents [<a href="#rid17">17</a>], but the risk factors and incidence have not been determined, nor has the exact timing after a dose to reach a level of anticoagulant effect safe for neuraxial anesthesia. </p><p>American Society of Regional Anesthesia and Pain Medicine (ASRA) recommends avoiding spinal or epidural techniques until nearly all of the medication has been eliminated (eg, five elimination half-lives for 97 percent elimination). For all of the oral direct factor Xa inhibitors, ASRA recommends an interval of 72 hours between the last dose and neuraxial anesthesia, despite widely differing half-lives for different factor Xa inhibitors. (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Interval since last dose'</a>.)</p><p>The European Society of Anesthesiology and Intensive Care/European Society of Regional Anesthesia (ESAIC/ESRA) guidelines make different recommendations for patients who receive low versus high dose <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> or <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, as described in the sections below  (<a class="graphic graphic_table graphicRef138528" href="/z/d/graphic/138528.html" rel="external">table 2</a>) [<a href="#rid22">22</a>]. </p><p>Routine laboratory testing is not used for determining anticoagulation status in patients receiving direct factor Xa inhibitors. Prolonged coagulation tests can be helpful in determining residual anticoagulant effect, but a normal prothrombin time/international normalized ratio (PT/INR) cannot be used as evidence that the anticoagulant effect has resolved. Specific assays for anti-factor Xa activity that are calibrated to the individual anticoagulant may be used if available in a timely fashion; if this testing is normal, then the result can be presumed to show that there is no residual anticoagulant effect. (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Assessment of anticoagulation status'</a>.)</p><p>The US Food and Drug Administration (FDA) has issued black box warnings on the risk of SEH with neuraxial anesthesia in patients treated with the direct oral factor Xa inhibitors [<a href="#rid44">44</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a><strong> (Xarelto) </strong>– Rivaroxaban has a half-life of five to nine hours, which may be prolonged to 11 to 13 hours in older patients. Dose adjustments at required for patients with renal or hepatic insufficiency. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Rivaroxaban'</a>.)</p><p></p><p class="bulletIndent1">The ASRA guidelines suggest that neuraxial anesthesia should be performed no sooner than 72 hours after the last dose of <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>. A rivaroxaban specific anti-factor Xa level may be measured, but a safe level of activity (other than zero) has not been determined. The first postoperative dose should be administered at least six hours after a neuraxial procedure or catheter removal; neuraxial catheters should be removed prior to the first postoperative dose. </p><p></p><p class="bulletIndent1">In the event of that <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> is mistakenly given to a patient with a neuraxial catheter in place, rivaroxaban should be withheld for 22 to 26 hours, or a rivaroxaban specific anti-factor Xa level should be measured to confirm lack of effect, prior to catheter removal.</p><p></p><p class="bulletIndent1">The ESAIC/ESRA guidelines define low dose <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> as 2.5 mg twice daily or 10 mg once daily; they define high dose as 15 mg twice daily or 20 mg once daily when used for venous thromboembolism (VTE) treatment or atrial fibrillation [<a href="#rid22">22</a>]. They consider 20 mg once daily when used for extended thromboprophylaxis to be low dose [<a href="#rid22">22</a>]. The guideline recommends waiting at least 24 hours after low dose, and at least 72 hours after high dose rivaroxaban before a neuraxial procedure. However, for individuals receiving the 20 mg once daily dose, it may be prudent to observe an interval of 72 hours, regardless of indication, based on the pharmacokinetics of the drug. The first postoperative dose should be administered at least six hours after the procedure or catheter removal, longer after a traumatic procedure.</p><p></p><p class="bulletIndent1">The FDA warning stipulates that if a traumatic neuraxial procedure occurs, administration of <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> should be delayed for at least 24 hours [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">Apixaban</a><strong> (Eliquis) </strong>–<strong> </strong>The half-life of apixaban is approximately 12 hours (range, 8 to 15 hours), and may be prolonged in patients with renal dysfunction and in older patients. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Apixaban'</a>.)</p><p></p><p class="bulletIndent1">ASRA guidelines suggest that neuraxial anesthesia should occur no sooner than 72 hours after the last dose of <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>. The first postoperative dose should be administered at least six hours after a neuraxial procedure or catheter removal; neuraxial catheters should be removed prior to the first postoperative dose. If an unanticipated dose of apixaban is administered while a neuraxial catheter is in place, apixaban should be withheld for 26 to 30 hours, or an apixaban-specific anti Xa level should be measured. The FDA warning on apixaban stipulates that if a traumatic neuraxial procedure occurs, apixaban should be withheld for at least 48 hours [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent1">The ESAIC/ESRA guidelines define low dose <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> as 2.5 mg twice daily (as long as certain criteria are absent, such as age ≥80 years, body weight &lt;60 kg, or chronic kidney impairment), and high dose as 5 or 10 mg twice daily [<a href="#rid22">22</a>]. The guideline recommends waiting at least 36 hours after low dose apixaban, and at least 72 hours after high dose apixaban, before performing a neuraxial procedure. The first postoperative dose should be administered at least 6 hours after the procedure or catheter removal, longer after a traumatic procedure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">Edoxaban</a><strong> (Savaysa, Lixiana) </strong>– The half-life of edoxaban is approximately 6 to 11 hours. It is primarily excreted by the kidneys, and dose adjustment is recommended for patients with renal insufficiency. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Edoxaban'</a>.)</p><p></p><p class="bulletIndent1">ASRA and ESAIC/ESRA guidelines suggest that neuraxial anesthesia should occur no sooner than 72 hours after the last dose of <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> [<a href="#rid17">17,22</a>]. The first postoperative dose should be administered at least six hours after a neuraxial procedure or catheter removal; neuraxial catheters should be removed prior to the first postoperative dose. If an unanticipated dose of edoxaban is administered while a neuraxial catheter is in place, edoxaban should be withheld for 20 to 28 hours, or an edoxaban specific anti Xa level should be measured, before the catheter is removed. </p><p></p><p>Reversal of direct factor Xa inhibitors is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Factor Xa inhibitors'</a>.)</p><p class="headingAnchor" id="H174769712"><span class="h2">Dabigatran (Pradaxa)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">Dabigatran</a> is an oral direct thrombin inhibitor. Dabigatran is administered for postoperative thromboprophylaxis after orthopedic surgery, prevention and treatment of deep vein thrombosis, and stroke prevention in nonvalvular atrial fibrillation. There are no reported cases of SEH related to neuraxial anesthesia, but there are reports of a spontaneous SEH [<a href="#rid47">47</a>] and one related to a fall [<a href="#rid48">48</a>] in patients taking dabigatran. The FDA has issued a black box warning for SEH with neuraxial anesthesia or lumbar puncture, without recommendation for optimal timing.</p><p class="bulletIndent1">The half-life of <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> is approximately 12 to 17 hours in patients with normal kidney function. It is highly dependent on renal excretion, and the ASRA's recommendations for anesthetic management are based partly on estimates of the patient's renal function. For intervals less than those specified in the recommendations, a dilute thrombin time (dTT) or ecarin clotting time may be used to determine residual dabigatran activity, though safe levels have not been determined. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Monitoring argatroban and hirudin'</a> and  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Coagulation testing'</a>.)</p><p></p><p class="bulletIndent1">If necessary, <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> can be reversed with <a class="drug drug_general" data-topicid="104819" href="/z/d/drug information/104819.html" rel="external">idarucizumab</a>, which is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Dabigatran reversal'</a>.)</p><p></p><p class="bulletIndent1">ASRA recommends the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients in whom creatinine clearance (CrCl) has not be determined, perform neuraxial anesthesia no sooner than five days after the last dose. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients in whom CrCl has been determined, and without other risk factors for bleeding (eg, age &gt;65 years, hypertension, concomitant antiplatelet therapy), recommendations are as follows:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with CrCl &lt;30 mL/min who have received <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, do not perform neuraxial anesthesia.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with CrCl 30 to 49 mL/min perform neuraxial anesthesia no sooner than five days after the last dose.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with CrCl 50 to 79, perform neuraxial anesthesia no sooner than four days after the last dose.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with CrCl ≥80 mL/min, perform neuraxial anesthesia no sooner than three days (72 hours) after the last dose.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The first postoperative dose of <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> should be administered at least six hours after a neuraxial procedure or catheter removal; neuraxial catheters should be removed prior to the first postoperative dose.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If an unanticipated dose of <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> is administered while a neuraxial catheter is in place, dabigatran should be withheld for 34 to 36 hours or a dTT or ECT assessed before the catheter removal. </p><p></p><p class="bulletIndent1">The ESAIC/ESRA guidelines make a distinction between low and high dose <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> [<a href="#rid22">22</a>], as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who receive low dose <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> (220 mg once daily, or 150 mg once daily if CrCl is 30 to 50 mL/minute or age ≥75), perform neuraxial anesthesia at least 48 hours after the last dose.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who receive high dose <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> (150 mg twice daily, or 110 or 150 mg twice daily if CrCl is &lt; 50 mL/min or age 75 to 80, or 110 mg twice daily if age ≥ 80), perform neuraxial procedure at least 72 hours after the last dose. For patients with CrCl &lt;50 mL/min, perform neuraxial anesthesia after direct thrombin inhibitor level &lt;30 ng/mL or thrombin time is normal. In contrast with the ASRA guidelines, ESAIC/ESRA recommends administering the first postoperative dose at least 24 hours after a neuraxial procedure.</p><p></p><p class="headingAnchor" id="H3120092449"><span class="h1">FONDAPARINUX (ARIXTRA)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> is an injectable drug (subcutaneous) that may be used as an alternative to heparin for postoperative venous thromboembolism prophylaxis. It inhibits factor Xa indirectly by binding to antithrombin. Fondaparinux is a long-acting drug with plasma half-life of 17 to 21 hours [<a href="#rid49">49</a>], which is prolonged in patients with renal dysfunction [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement", section on 'Approach to pharmacologic thromboprophylaxis (low-risk bleeding)'</a> and  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients", section on 'Pharmacologic dosing'</a>.)</p><p>Experience with <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in patients who undergo neuraxial anesthesia is limited. During initial dose finding studies, one case of spinal epidural hematoma (SEH) was reported in a patient who received high dose fondaparinux after difficult epidural catheter placement (five attempts) [<a href="#rid50">50</a>].</p><p>For patients who have received <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>, the European Society of Anesthesiology and Intensive Care/European Society of Regional Anesthesia (ESAIC/ESRA) guidelines recommend that neuraxial anesthesia should not be performed until 36 hours after the last dose (or until 72 hours after the last dose if the CrCL is &lt;50 mL/minute) [<a href="#rid22">22</a>]. American Society of Regional Anesthesia and Pain Medicine (ASRA) guidelines make no recommendation on preoperative administration; they recommend that fondaparinux should not be administered for postoperative thromboprophylaxis after difficult neuraxial procedures (ie, more than one needle pass, difficulty threading a neuraxial catheter), and should not be administered for patients with an indwelling neuraxial catheter. A neuraxial catheter should be removed at least six hours prior to the first postoperative dose of fondaparinux. </p><p>Fondaparinux-specific anti-factor Xa assays are available, but optimal therapeutic levels and safe levels for performance of neuraxial anesthesia have not been determined. </p><p class="headingAnchor" id="H262596002"><span class="h1">PARENTERAL DIRECT THROMBIN INHIBITORS</span><span class="headingEndMark"> — </span>This class of anticoagulants includes <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">argatroban</a> and <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a>, which are used for anticoagulation in patients with heparin-induced thrombocytopenia (HIT). Neuraxial anesthesia is not recommended in patients who are receiving these medications. The anticoagulant effects of direct thrombin inhibitors may be monitored with an activated partial thromboplastin time (aPTT). The parenteral direct thrombin inhibitors do not have specific reversal agents, but their half-lives are very short and thus their effect on coagulation status reverses relatively soon after discontinuation. </p><p>Neither the American Society of Regional Anesthesia and Pain Medicine (ASRA) nor the European Society of Anesthesiology and Intensive Care/European Society of Regional Anesthesia (ESAIC/ESRA) guidelines make recommendations on the timing of neuraxial anesthesia after discontinuation of <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">argatroban</a> or <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> [<a href="#rid17">17,39</a>]. The ESIAC/ESRA guidelines note that these drugs are primarily used in critically ill patients who are not likely to receive regional anesthesia. Nevertheless, the 2010 ESRA guidelines suggested delaying neuraxial anesthesia for at least four hours after discontinuation of argatroban, and waiting two hours after a neuraxial procedure or catheter removal to administer a subsequent dose [<a href="#rid39">39</a>]. Regardless of the interval, a normal aPTT should be documented prior to neuraxial anesthesia.</p><p class="headingAnchor" id="H703631086"><span class="h1">ANTIPLATELET DRUGS</span><span class="headingEndMark"> — </span>The antiplatelet drugs include <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, nonsteroidal antiinflammatory drugs (NSAIDS), the direct and indirect platelet P2Y12 receptor blockers, the platelet GP IIb/IIIa receptor antagonists, and other individual antiplatelet agents. Antiplatelet therapy is increasingly used for management and prevention of cardiac and cerebrovascular ischemia. (See  <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"</a> and  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a>.)</p><p class="headingAnchor" id="H1756249928"><span class="h2">Aspirin and other nonsteroidal antiinflammatory drugs</span><span class="headingEndMark"> — </span>As single drugs, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and other NSAIDs can be used in patients receiving spinal or epidural anesthesia or analgesia; there is no evidence of an increased risk of spinal epidural hematoma (SEH) [<a href="#rid51">51</a>].</p><p>In patients receiving other antithrombotic medications, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> should be stopped 7 to 10 days prior to neuraxial anesthesia if clinically appropriate (because aspirin causes dysfunction for the life of the platelet), and other NSAIDs should be stopped three days before a neuraxial anesthetic to allow for full return of platelet function [<a href="#rid52">52</a>]. Cyclooxygenase-2 (COX-2) inhibitors have minimal effects on platelet function and may be used together with antithrombotic medications, with the exception of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, in patients having neuraxial anesthesia. The concomitant use of COX-2 inhibitors and warfarin may increase the risk of hemorrhagic complications [<a href="#rid53">53</a>]. (See <a class="local">'Multiple antithrombotic drugs'</a> above.)</p><p>Recommendations regarding <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> differ in the American Society of Regional Anesthesia and Pain Medicine (ASRA) and European Society of Anesthesiology and Intensive Care/European Society of Regional Anesthesia (ESAIC/ESRA) guidelines. The ASRA guidelines do not recommend changes to the timing of neuraxial procedures or catheter removal in patients receiving aspirin alone [<a href="#rid17">17</a>]. In contrast, the ESAIC/ESRA guidelines recommend discontinuing high dose aspirin (defined as ≥200 mg/day) for three days in patients with normal platelet counts and seven days in others, prior to performing neuraxial anesthesia, and waiting at least six hours after neuraxial procedures or catheter removal before administering the first postoperative dose [<a href="#rid22">22</a>]. The variation in opinions between the guideline panels may relate to different interpretations of clinical or laboratory data regarding the mechanism of action of aspirin at different doses.</p><p class="headingAnchor" id="H1134523396"><span class="h2">Platelet P2Y12 receptor blockers</span><span class="headingEndMark"> — </span>The thienopyridines (<a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a>, and <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a>) irreversibly antagonize ADP-induced platelet aggregation by inhibition of the P2Y12 receptor after metabolism via hepatic CYP 450 system [<a href="#rid54">54</a>]. Their effects last 4 to 10 days after the drugs have been discontinued. (See  <a class="medical medical_review" href="/z/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs", section on 'ADP receptors (P2Y1 and P2Y12)'</a>.)</p><p><a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">Ticagrelor</a> reversibly inhibits platelet aggregation by a direct action on the platelet P2Y12 receptor. Spontaneous SEH has been reported during <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> therapy [<a href="#rid55">55</a>], and SEH has been reported after neuraxial anesthesia during clopidogrel or <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> therapy [<a href="#rid56">56-58</a>]. </p><p>The ASRA guidelines for neuraxial anesthesia with these medications are consistent with guidelines from the ESAIC/ESRA and the American College of Chest Physicians (ACCP) [<a href="#rid17">17,22,59</a>], as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The time intervals between the last dose of the medication and neuraxial anesthesia should be as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> (Plavix) – 5 to 7 days</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">Prasugrel</a> (Effient) – 7 to 10 days</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">Ticlopidine</a> (not available in the United States) – 10 days</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">Ticagrelor</a> (Brilinta) – 5 to 7 days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuraxial catheters should not be maintained with <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> because of rapid onset of action. Epidural catheters may be maintained for one or two days after reinstitution of therapy with <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a>, as long as a loading dose is not administered; if a loading dose is to be administered, it should be administered at least six hours after a neuraxial procedure or catheter removal.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="102219" href="/z/d/drug information/102219.html" rel="external">Cangrelor</a> (Kengreal) is a short acting P2Y12 inhibitor that is administered by infusion. It may be used for bridging therapy after oral agents are discontinued. ASRA suggests that cangrelor should be discontinued at least three hours prior to neuraxial anesthesia. Neuraxial catheters should be removed prior to starting cangrelor therapy, and the first postoperative dose should be administered at least eight hours after a neuraxial procedure or catheter removal. </p><p></p><p class="headingAnchor" id="H872112749"><span class="h2">Platelet GPIIb/IIIa receptor antagonists</span><span class="headingEndMark"> — </span>These are intravenous drugs that block platelet aggregation (see  <a class="medical medical_review" href="/z/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs", section on 'GPIIb/IIIa inhibitors'</a>). They are used primarily for therapy of acute coronary syndrome, usually in combination with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and heparin. Neuraxial anesthesia should be avoided for four to eight hours after administration of <a class="drug drug_general" data-topicid="8918" href="/z/d/drug information/8918.html" rel="external">eptifibatide</a> (Integrilin) or <a class="drug drug_general" data-topicid="10288" href="/z/d/drug information/10288.html" rel="external">tirofiban</a> (Aggrastat) and for 24 to 48 hours after abciximab. </p><p>Use of these drugs is contraindicated for four weeks after major surgery [<a href="#rid60">60-62</a>]; patients should be carefully monitored neurologically if a dose is given in the month following a neuraxial needle or catheter placement, and any neuraxial catheter infusions adjusted to eliminate motor block and allow neurologic monitoring.</p><p class="headingAnchor" id="H3520099917"><span class="h2">Cilostazol (Pletal)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">Cilostazol</a> reversibly inhibits platelet aggregation by inhibiting PDE IIIA. It is used primarily for peripheral arterial disease. The elimination half-life is approximately 11 to 13 hours and is prolonged in patients with renal failure [<a href="#rid63">63</a>]. SEH has been reported following epidural catheter removal during cilostazol therapy [<a href="#rid64">64</a>]. The risk of bleeding associated with neuraxial anesthesia during cilostazol therapy is unknown. Based on elimination half-life, ASRA suggests that neuraxial anesthesia should be performed no sooner than two days after the last dose. The first postoperative dose of cilostazol should be administered at least six hours after a neuraxial procedure or catheter removal; neuraxial catheters should be removed prior to the first postoperative dose.</p><p class="headingAnchor" id="H3896843201"><span class="h2">Dipyridamole (Persantine)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">Dipyridamole</a> impairs platelet function by inhibiting the activity of adenosine deaminase and phosphodiesterase, and may be used for stroke prevention, particularly in combination with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. The half-life of elimination is 10 to 12 hours. (See  <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke", section on 'Aspirin plus dipyridamole'</a>.) </p><p>Spinal hematoma has not been reported after neuraxial anesthesia, but hematomas have been reported after peripheral nerve block during <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> therapy [<a href="#rid65">65,66</a>].</p><p>ASRA suggests that neuraxial anesthesia should be performed no sooner than 24 hours after the last dose of extended release <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a>. The first postoperative dose should be administered at least six hours after a neuraxial procedure or catheter removal; neuraxial catheters should be removed prior to the first postoperative dose.</p><p class="headingAnchor" id="H35862184"><span class="h1">THROMBOLYTIC OR FIBRINOLYTIC THERAPY</span><span class="headingEndMark"> — </span>Plasminogen activators (streptokinase, urokinase, <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">alteplase</a>, <a class="drug drug_general" data-topicid="9955" href="/z/d/drug information/9955.html" rel="external">tenecteplase</a>) activate plasminogen to plasmin to dissolve fibrin clot, resulting in reduced levels of circulating plasminogen and fibrinogen. Despite relatively short plasma half-lives, the thrombolytic effect of these drugs may persist for days. The incidence of spinal epidural hematoma (SEH) in patients receiving thrombolytic/fibrinolytic therapy is unknown. However, both spontaneous spinal or epidural hematoma and neuraxial anesthesia-related SEH have been reported during or prior to thrombolytic therapy [<a href="#rid67">67-72</a>]. There are no data addressing the length of time that neuraxial anesthesia should be avoided after discontinuation of these drugs. A cautious approach is to avoid spinal or epidural techniques for five elimination half-lives (ie, 97 percent elimination). The American Society of Regional Anesthesia and Pain Medicine (ASRA) suggests avoiding neuraxial anesthesia for 48 hours after discontinuation of thrombolytic/fibrinolytic medications, and documentation of normal clotting parameters and fibrinogen level. In patients who require thrombolytic therapy near the time of neuraxial block, frequent neurologic monitoring should performed to assess for signs of SEH. </p><p>No recommendations are available to guide removal of a neuraxial catheter in patients who received thrombolytic therapy after initial catheter placement. In this extremely rare situation, the fibrinogen level may be measured to assist in timing of catheter removal, though a safe level of fibrinogen has not been determined.</p><p class="headingAnchor" id="H262596287"><span class="h1">HERBAL PRODUCTS</span><span class="headingEndMark"> — </span>Several widely used herbal products affect platelet function, including garlic, ginkgo, and ginseng, although the effects are not well quantified and may vary with different preparations. There are reports of spontaneous neuraxial bleeding in patients who have ingested garlic [<a href="#rid73">73</a>] and ginkgo biloba [<a href="#rid74">74</a>], and reports of other significant bleeding in patients who were taking ginkgo biloba. The risk of bleeding theoretically may be further increased if herbal substances (eg, garlic, ginseng, ginger, ginkgo biloba) are taken together or in combination with medications that affect hemostasis. (See  <a class="medical medical_review" href="/z/d/html/1387.html" rel="external">"Clinical use of ginkgo biloba", section on 'Safety'</a> and  <a class="medical medical_review" href="/z/d/html/1387.html" rel="external">"Clinical use of ginkgo biloba", section on 'Potential interactions'</a>.) </p><p>There are no reported cases of spinal epidural hematoma (SEH) after neuraxial anesthesia thought to be related to the use of herbal products. Therefore, we agree with the guidelines from American Society of Regional Anesthesia and Pain Medicine (ASRA) that herbal products do not need to be withheld prior to neuraxial anesthesia. The joint guidelines on interventional pain procedures in patients taking antiplatelet and anticoagulant medications recommends discontinuation of herbal products that affect hemostasis prior to high-risk interventional procedures (eg, spinal cord simulator placement, intrathecal catheter placement, vertebral augmentation), but not before intermediate-risk procedures (eg, epidural steroid injection, sympathetic blocks) or low-risk procedures (eg, peripheral nerve blocks, trigger point injections, implantable pulse generator replacement) [<a href="#rid1">1</a>]. </p><p>There are no data regarding the risk of SEH in patients who take a combination of herbal products or the combination of herbal product with antithrombotic medication.</p><p class="headingAnchor" id="H703631320"><span class="h1">PREVENTION OF NEUROLOGIC DAMAGE FROM SPINAL HEMATOMA</span><span class="headingEndMark"> — </span>The best chance of neurologic recovery after spinal epidural hematoma (SEH) depends on rapid diagnosis and management. Strategies for reducing the risk of SEH are shown in a table  (<a class="graphic graphic_table graphicRef118905" href="/z/d/graphic/118905.html" rel="external">table 3</a>). (See <a class="local">'Typical presentation'</a> above.)</p><p class="headingAnchor" id="H703630956"><span class="h2">Neurologic monitoring</span><span class="headingEndMark"> — </span>Sensory and motor function should be monitored in all patients receiving neuraxial anesthesia or analgesia, whether or not they receive antithrombotic therapy. (See  <a class="medical medical_review" href="/z/d/html/118479.html" rel="external">"Continuous epidural analgesia for postoperative pain: Technique and management", section on 'Monitoring during epidural analgesia'</a>.)</p><p>Frequent checks (ie, every one to two hours) are necessary during the 6 to 12 hours after initiation of a new anticoagulant regimen for patients with an epidural catheter in place. Neurologic checks can occur less frequently thereafter. Any change in neurologic status that is not clearly explained by epidural bolus or change in local anesthetic concentration should immediately trigger clinical assessment and further evaluation.</p><p>During epidural analgesia, use of the smallest effective concentration of local anesthetic will allow for earlier recognition of sensory or motor changes. </p><p class="headingAnchor" id="H703631328"><span class="h2">Evaluation, management, and prognosis</span><span class="headingEndMark"> — </span>Emergency magnetic resonance imaging (MRI; or emergency computed tomography scan [CT] if MRI is contraindicated or unavailable) is recommended as soon as SEH is suspected. If SEH is detected, any residual anticoagulant should be reversed rapidly if appropriate (ie, if anticoagulant effect is present). Reversal strategies are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Serious/life-threatening bleeding'</a> and  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Major bleeding'</a>.)</p><p>Emergency neurosurgical consultation should be arranged to evaluate for decompressive surgery. Neurologic recovery is more likely if decompressive laminectomy is performed within eight hours of symptom onset. In a retrospective case series of 61 SEHs, patients with decompressive surgery less than eight hours after onset of paraplegia had better neurologic outcomes (6/13 good recovery, 4/13 partial recovery, 3/13 poor recovery) than if surgery was over 24 hours after symptom onset (2/12 good recovery, 10/12 poor recovery) [<a href="#rid28">28</a>]. Even with prompt diagnosis and decompression, many patients have permanent neurologic deficits. The final neurologic outcome depends on [<a href="#rid28">28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The time span between hematoma formation and surgical decompression</p><p class="bulletIndent1"><span class="glyph">●</span>The speed with which the hematoma develops</p><p class="bulletIndent1"><span class="glyph">●</span>The severity of the preoperative neurologic deficit</p><p class="bulletIndent1"><span class="glyph">●</span>The size of the hematoma</p><p></p><p class="headingAnchor" id="H827781657"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/129632.html" rel="external">"Society guideline links: Local and regional anesthesia"</a>.)</p><p class="headingAnchor" id="H703631274"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of SEH with neuraxial procedures</strong> – Patients using anticoagulants and certain antiplatelet agents are at increased risk for spinal epidural hematoma (SEH) after neuraxial anesthesia. The risk is estimated to be 1 in 18,000 for epidural anesthetics, and 1 in 158,000 for spinal anesthetics. Additional risk factors include bleeding diatheses, timing of antithrombotic drugs in relation to neuraxial needle placement or catheter removal, difficult or traumatic (bloody) placement, spinal abnormalities, female sex, and possibly older age. (See <a class="local">'Incidence and risk factors for SEH after neuraxial anesthesia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Strategies to reduce risk</strong> – Patients with multiple risk factors for SEH may have the risk decreased by using a smaller needle (spinal rather than epidural) and by avoiding a continuous catheter technique. (See <a class="local">'Decision to use neuraxial anesthesia in patients on antithrombotic medication'</a> above and <a class="local">'Spinal versus epidural technique'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recommendations for specific medications</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>More than one antithrombotic</strong> – Use of more than one antithrombotic medication increases the risk of SEH. In patients with more than one antithrombotic medication (including <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or another nonsteroidal antiinflammatory drug [NSAID] in effect at the time of the procedure), we recommend avoiding neuraxial anesthetic techniques (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Multiple antithrombotic drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anticoagulants</strong> – Patients receiving an anticoagulant during the periprocedural period require attention to the timing of drug administration and drug dosing when a spinal or epidural catheter is used; this includes unfractionated and low molecular weight heparin (LMWH), <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, direct oral anticoagulants (<a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>, <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>), and <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>. Recommendations based on the guidelines of the American Society of Regional Anesthesia (ASRA; 2018) are summarized in the table  (<a class="graphic graphic_table graphicRef87862" href="/z/d/graphic/87862.html" rel="external">table 1</a>). Recommendations from the European Society of Anaesthesiology and Intensive Care and the European Society of Regional Anaesthesia are summarized in a separate table  (<a class="graphic graphic_table graphicRef138528" href="/z/d/graphic/138528.html" rel="external">table 2</a>). (See <a class="local">'Guidelines for timing of neuraxial anesthesia procedures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antiplatelet agents</strong> – There should be a delay of 5 to 7 days between <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> and neuraxial anesthesia; longer intervals are required for <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> and <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> and shorter intervals for <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> and GPIIb/IIIa inhibitors. Single agent <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or another NSAID does not appear to increase the risk of SEH after a neuraxial technique and does not require discontinuation. (See <a class="local">'Antiplatelet drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Herbal products</strong> – Patients using herbal products that affect platelet function (eg, garlic, ginkgo, and ginseng) may be considered for neuraxial anesthesia since there is no evidence of increased risk of SEH. Administration of combinations of herbal medicines that are thought to affect hemostasis or administration of these medicines along with other drugs that affect hemostasis may increase the risk of bleeding. (See <a class="local">'Herbal products'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for complications</strong> – Patients having neuraxial anesthesia who have received any antithrombotic drug in the periprocedural period need frequent neurologic examinations, particularly noting motor and sensory function at and below the level of the neuraxial technique. Especially in patients with multiple risk factors for SEH, the lowest effective dose of local anesthetic for perioperative analgesia will allow for earlier recognition of motor or sensory loss caused by SEH. (See <a class="local">'Neurologic monitoring'</a> above and <a class="local">'Typical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation for symptoms</strong> – Patients with significant symptoms leading to suspicion of SEH should have emergency imaging with magnetic resonance imaging (MRI) or computed tomography (CT), and emergency neurosurgical evaluation for possible decompressive surgery. Long-term neurologic outcome of SEH is better if decompressive surgery is performed less than eight hours after symptom onset. (See <a class="local">'Evaluation, management, and prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H28926932"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff thank Dr. John Stanec for his contributions as an author to previous versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Narouze S, Benzon HT, Provenzano D, et al. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med 2018; 43:225.</a></li><li><a class="nounderline abstract_t">Figueroa J, DeVine JG. Spontaneous spinal epidural hematoma: literature review. J Spine Surg 2017; 3:58.</a></li><li><a class="nounderline abstract_t">An JX, Fang QW, Sullivan EA, Williams JP. Spine surgery may cause more spinal epidural hematomas than spinal puncture. Chin Med J (Engl) 2013; 126:286.</a></li><li><a class="nounderline abstract_t">Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology 2004; 101:950.</a></li><li><a class="nounderline abstract_t">Bateman BT, Mhyre JM, Ehrenfeld J, et al. The risk and outcomes of epidural hematomas after perioperative and obstetric epidural catheterization: a report from the Multicenter Perioperative Outcomes Group Research Consortium. Anesth Analg 2013; 116:1380.</a></li><li><a class="nounderline abstract_t">Tryba M. [Epidural regional anesthesia and low molecular heparin: Pro]. Anasthesiol Intensivmed Notfallmed Schmerzther 1993; 28:179.</a></li><li><a class="nounderline abstract_t">D'Angelo R, Smiley RM, Riley ET, Segal S. Serious complications related to obstetric anesthesia: the serious complication repository project of the Society for Obstetric Anesthesia and Perinatology. Anesthesiology 2014; 120:1505.</a></li><li><a class="nounderline abstract_t">Leffert LR, Dubois HM, Butwick AJ, et al. Neuraxial Anesthesia in Obstetric Patients Receiving Thromboprophylaxis With Unfractionated or Low-Molecular-Weight Heparin: A Systematic Review of Spinal Epidural Hematoma. Anesth Analg 2017; 125:223.</a></li><li><a class="nounderline abstract_t">Vandermeulen E. Anaesthesia and new antithrombotic drugs. Curr Opin Anaesthesiol 2005; 18:353.</a></li><li><a class="nounderline abstract_t">Ehrenfeld JM, Agarwal AK, Henneman JP, Sandberg WS. Estimating the incidence of suspected epidural hematoma and the hidden imaging cost of epidural catheterization: a retrospective review of 43,200 cases. Reg Anesth Pain Med 2013; 38:409.</a></li><li><a class="nounderline abstract_t">Schroeder DR. Statistics: detecting a rare adverse drug reaction using spontaneous reports. Reg Anesth Pain Med 1998; 23:183.</a></li><li><a class="nounderline abstract_t">Ballin NC. Paraplegia following epidural analgesia. Anaesthesia 1981; 36:952.</a></li><li><a class="nounderline abstract_t">Yuen TS, Kua JS, Tan IK. Spinal haematoma following epidural anaesthesia in a patient with eclampsia. Anaesthesia 1999; 54:350.</a></li><li><a class="nounderline abstract_t">Horlocker TT, Wedel DJ. Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998; 23:164.</a></li><li><a class="nounderline abstract_t">Lee LA, Posner KL, Domino KB, et al. Injuries associated with regional anesthesia in the 1980s and 1990s: a closed claims analysis. Anesthesiology 2004; 101:143.</a></li><li><a class="nounderline abstract_t">Leffert L, Butwick A, Carvalho B, et al. The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the Anesthetic Management of Pregnant and Postpartum Women Receiving Thromboprophylaxis or Higher Dose Anticoagulants. Anesth Analg 2018; 126:928.</a></li><li><a class="nounderline abstract_t">Horlocker TT, Vandermeuelen E, Kopp SL, et al. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med 2018; 43:263.</a></li><li><a class="nounderline abstract_t">Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:257S.</a></li><li><a class="nounderline abstract_t">Ruff RL, Dougherty JH Jr. Complications of lumbar puncture followed by anticoagulation. Stroke 1981; 12:879.</a></li><li><a class="nounderline abstract_t">Rao TL, El-Etr AA. Anticoagulation following placement of epidural and subarachnoid catheters: an evaluation of neurologic sequelae. Anesthesiology 1981; 55:618.</a></li><li><a class="nounderline abstract_t">Working Party:, Association of Anaesthetists of Great Britain &amp; Ireland, Obstetric Anaesthetists' Association, Regional Anaesthesia UK. Regional anaesthesia and patients with abnormalities of coagulation: the Association of Anaesthetists of Great Britain &amp; Ireland The Obstetric Anaesthetists' Association Regional Anaesthesia UK. Anaesthesia 2013; 68:966.</a></li><li><a class="nounderline abstract_t">Kietaibl S, Ferrandis R, Godier A, et al. Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines. Eur J Anaesthesiol 2022; 39:100.</a></li><li><a class="nounderline abstract_t">Breivik H, Bang U, Jalonen J, et al. Nordic guidelines for neuraxial blocks in disturbed haemostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. Acta Anaesthesiol Scand 2010; 54:16.</a></li><li><a class="nounderline abstract_t">Kozek-Langenecker SA, Fries D, Gütl M, et al. [Locoregional anesthesia and coagulation inhibitors. Recommendations of the Task Force on Perioperative Coagulation of the Austrian Society for Anesthesiology and Intensive Care Medicine]. Anaesthesist 2005; 54:476.</a></li><li><a class="nounderline abstract_t">Llau Pitarch JV, De Andrés Ibáñez J, Gomar Sancho C, et al. [Hemostasis-altering drugs and techniques for regional anesthesia and analgesia: safety recommendations]. Rev Esp Anestesiol Reanim 2005; 52:248.</a></li><li><a class="nounderline abstract_t">Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.</a></li><li><a class="nounderline abstract_t">Baglin T, Barrowcliffe TW, Cohen A, et al. Guidelines on the use and monitoring of heparin. Br J Haematol 2006; 133:19.</a></li><li><a class="nounderline abstract_t">Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994; 79:1165.</a></li><li><a class="nounderline abstract_t">Liu SS, Mulroy MF. Neuraxial anesthesia and analgesia in the presence of standard heparin. Reg Anesth Pain Med 1998; 23:157.</a></li><li><a class="nounderline abstract_t">Ho AM, Li PT, Karmakar MK. Risk of hematoma after epidural anesthesia and analgesia for cardiac surgery. Anesth Analg 2006; 103:1327; author reply 1327.</a></li><li><a class="nounderline abstract_t">Chaney MA. Intrathecal and epidural anesthesia and analgesia for cardiac surgery. Anesth Analg 2006; 102:45.</a></li><li><a class="nounderline abstract_t">Royse CF. High thoracic epidural anaesthesia for cardiac surgery. Curr Opin Anaesthesiol 2009; 22:84.</a></li><li><a class="nounderline abstract_t">Ho AM, Chung DC, Joynt GM. Neuraxial blockade and hematoma in cardiac surgery: estimating the risk of a rare adverse event that has not (yet) occurred. Chest 2000; 117:551.</a></li><li><a class="nounderline abstract_t">Gallus AS, Hirsh J, Tutle RJ, et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973; 288:545.</a></li><li><a class="nounderline abstract_t">Matsubara S, Usui R, Ohkuchi A, et al. Prolonged activated partial thromboplastin time in thromboprophylaxis with unfractionated heparin in patients undergoing cesarean section. J Obstet Gynaecol Res 2010; 36:58.</a></li><li><a class="nounderline abstract_t">Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S.</a></li><li class="breakAll">https://www.fda.gov/Drugs/DrugSafety/ucm373595.htm.</li><li><a class="nounderline abstract_t">Lojewski B, Bacher P, Iqbal O, et al. Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period. Semin Thromb Hemost 1995; 21:228.</a></li><li><a class="nounderline abstract_t">Gogarten W, Vandermeulen E, Van Aken H, et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27:999.</a></li><li><a class="nounderline abstract_t">Woolson ST, Robinson RK, Khan NQ, et al. Deep venous thrombosis prophylaxis for knee replacement: warfarin and pneumatic compression. Am J Orthop (Belle Mead NJ) 1998; 27:299.</a></li><li><a class="nounderline abstract_t">Badenhorst CH. Epidural hematoma after epidural pain control and concomitant postoperative anticoagulation. Reg Anesth 1996; 21:272.</a></li><li><a class="nounderline abstract_t">Liu SS, Buvanendran A, Viscusi ER, et al. Uncomplicated removal of epidural catheters in 4365 patients with international normalized ratio greater than 1.4 during initiation of warfarin therapy. Reg Anesth Pain Med 2011; 36:231.</a></li><li><a class="nounderline abstract_t">Parvizi J, Viscusi ER, Frank HG, et al. Can epidural anesthesia and warfarin be coadministered? Clin Orthop Relat Res 2007; 456:133.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022406s019s020lbl.pdf.</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022406s015lbl.pdf (Accessed on April 16, 2018).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202155s018lbl.pdf (Accessed on April 16, 2018).</li><li><a class="nounderline abstract_t">Bamps S, Decramer T, Vandenbussche N, et al. Dabigatran-associated spontaneous acute cervical epidural hematoma. World Neurosurg 2015; 83:257.</a></li><li><a class="nounderline abstract_t">Truumees E, Gaudu T, Dieterichs C, et al. Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran). Spine (Phila Pa 1976) 2012; 37:E863.</a></li><li><a class="nounderline abstract_t">Turpie AG, Gallus AS, Hoek JA, Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344:619.</a></li><li><a class="nounderline abstract_t">Landow L. A synthetic pentasaccharide for the prevention of deep-vein thrombosis. N Engl J Med 2001; 345:291.</a></li><li><a class="nounderline abstract_t">Urmey WF, Rowlingson J. Do antiplatelet agents contribute to the development of perioperative spinal hematoma? Reg Anesth Pain Med 1998; 23:146.</a></li><li><a class="nounderline abstract_t">Cronberg S, Wallmark E, Söderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 1984; 33:155.</a></li><li><a class="nounderline abstract_t">Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. Ann Pharmacother 2000; 34:325.</a></li><li><a class="nounderline abstract_t">Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e89S.</a></li><li><a class="nounderline abstract_t">Morales Ciancio RA, Drain O, Rillardon L, Guigui P. Acute spontaneous spinal epidural hematoma: an important differential diagnosis in patients under clopidogrel therapy. Spine J 2008; 8:544.</a></li><li><a class="nounderline abstract_t">Benzon HT, Wong HY, Siddiqui T, Ondra S. Caution in performing epidural injections in patients on several antiplatelet drugs. Anesthesiology 1999; 91:1558.</a></li><li><a class="nounderline abstract_t">Kawaguchi S, Tokutomi S. [A case of epidural hematoma associated with epidural catheterization which occurred on 12th days after the last medication of ticlopidine hydrochloride]. Masui 2002; 51:526.</a></li><li><a class="nounderline abstract_t">Mayumi T, Dohi S. Spinal subarachnoid hematoma after lumbar puncture in a patient receiving antiplatelet therapy. Anesth Analg 1983; 62:777.</a></li><li><a class="nounderline abstract_t">Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e326S.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020718s037lbl.pdf.</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20912lbl.pdf.</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/abcicen110597-lab.pdf.</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020863s021lbl.pdf (Accessed on April 18, 2018).</li><li><a class="nounderline abstract_t">Kaneda T, Urimoto G, Suzuki T. Spinal epidural hematoma following epidural catheter removal during antiplatelet therapy with cilostazol. J Anesth 2008; 22:290.</a></li><li><a class="nounderline abstract_t">Clendenen SR, Robards CB, Wang RD, Greengrass RA. Case report: continuous interscalene block associated with neck hematoma and postoperative sepsis. Anesth Analg 2010; 110:1236.</a></li><li><a class="nounderline abstract_t">Parvaiz MA, Korwar V, McArthur D, et al. Large retroperitoneal haematoma: an unexpected complication of ilioinguinal nerve block for inguinal hernia repair. Anaesthesia 2012; 67:80.</a></li><li><a class="nounderline abstract_t">Ferrante A, Pedi C, Centamore G, et al. [ A rare complication of thrombolytic therapy: spinal epidural hematoma. A case report ]. Ital Heart J Suppl 2003; 4:688.</a></li><li><a class="nounderline abstract_t">Ozgocmen S, Yoldas T, Kocakoc E, et al. Spinal epidural hematoma associated with streptokinase treatment for myocardial infarction. Spinal Cord 2004; 42:374.</a></li><li><a class="nounderline abstract_t">Clark MA, Paradis NA. Spinal epidural hematoma complicating thrombolytic therapy with tissue plasminogen activator--a case report. J Emerg Med 2002; 23:247.</a></li><li><a class="nounderline abstract_t">Cultrera F, Passanisi M, Giliberto O, et al. Spinal epidural hematoma following coronary thrombolysis. A case report. J Neurosurg Sci 2004; 48:43.</a></li><li><a class="nounderline abstract_t">Baron EM, Burke JA, Akhtar N, Young WF. Spinal epidural hematoma associated with tissue plasminogen activator treatment of acute myocardial infarction. Catheter Cardiovasc Interv 1999; 48:390.</a></li><li><a class="nounderline abstract_t">Onishchuk JL, Carlsson C. Epidural hematoma associated with epidural anesthesia: complications of anticoagulant therapy. Anesthesiology 1992; 77:1221.</a></li><li><a class="nounderline abstract_t">Rose KD, Croissant PD, Parliament CF, Levin MB. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery 1990; 26:880.</a></li><li><a class="nounderline abstract_t">Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998; 50:1933.</a></li></ol></div><div id="topicVersionRevision">Topic 14930 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29278603" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28435919" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Spontaneous spinal epidural hematoma: literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23324278" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Spine surgery may cause more spinal epidural hematomas than spinal puncture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15448529" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Severe neurological complications after central neuraxial blockades in Sweden 1990-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504213" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The risk and outcomes of epidural hematomas after perioperative and obstetric epidural catheterization: a report from the Multicenter Perioperative Outcomes Group Research Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8391334" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : [Epidural regional anesthesia and low molecular heparin: Pro].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24845921" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Serious complications related to obstetric anesthesia: the serious complication repository project of the Society for Obstetric Anesthesia and Perinatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28628578" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Neuraxial Anesthesia in Obstetric Patients Receiving Thromboprophylaxis With Unfractionated or Low-Molecular-Weight Heparin: A Systematic Review of Spinal Epidural Hematoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534362" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anaesthesia and new antithrombotic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23924685" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Estimating the incidence of suspected epidural hematoma and the hidden imaging cost of epidural catheterization: a retrospective review of 43,200 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9845392" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Statistics: detecting a rare adverse drug reaction using spontaneous reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7304882" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Paraplegia following epidural analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10455833" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Spinal haematoma following epidural anaesthesia in a patient with eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9845390" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220784" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Injuries associated with regional anesthesia in the 1980s and 1990s: a closed claims analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29099429" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the Anesthetic Management of Pregnant and Postpartum Women Receiving Thromboprophylaxis or Higher Dose Anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29561531" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574268" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7303081" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Complications of lumbar puncture followed by anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7305052" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Anticoagulation following placement of epidural and subarachnoid catheters: an evaluation of neurologic sequelae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23905877" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Regional anaesthesia and patients with abnormalities of coagulation: the Association of Anaesthetists of Great Britain&amp;Ireland The Obstetric Anaesthetists' Association Regional Anaesthesia UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34980845" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19839941" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nordic guidelines for neuraxial blocks in disturbed haemostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15747141" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : [Locoregional anesthesia and coagulation inhibitors. Recommendations of the Task Force on Perioperative Coagulation of the Austrian Society for Anesthesiology and Intensive Care Medicine].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15901035" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : [Hemostasis-altering drugs and techniques for regional anesthesia and analgesia: safety recommendations].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315264" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16512825" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Guidelines on the use and monitoring of heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7978443" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Anticoagulants and spinal-epidural anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9845389" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Neuraxial anesthesia and analgesia in the presence of standard heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17056978" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk of hematoma after epidural anesthesia and analgesia for cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16368803" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intrathecal and epidural anesthesia and analgesia for cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19295296" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : High thoracic epidural anaesthesia for cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10669702" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neuraxial blockade and hematoma in cardiac surgery: estimating the risk of a rare adverse event that has not (yet) occurred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4568221" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Small subcutaneous doses of heparin in prevention of venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20178528" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prolonged activated partial thromboplastin time in thromboprophylaxis with unfractionated heparin in patients undergoing cesarean section.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574264" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574264" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7660145" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20890208" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9586729" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Deep venous thrombosis prophylaxis for knee replacement: warfarin and pneumatic compression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8744673" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Epidural hematoma after epidural pain control and concomitant postoperative anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21451439" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Uncomplicated removal of epidural catheters in 4365 patients with international normalized ratio greater than 1.4 during initiation of warfarin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17053565" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Can epidural anesthesia and warfarin be coadministered?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17053565" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Can epidural anesthesia and warfarin be coadministered?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17053565" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Can epidural anesthesia and warfarin be coadministered?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17053565" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Can epidural anesthesia and warfarin be coadministered?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25463422" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Dabigatran-associated spontaneous acute cervical epidural hematoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22343277" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11228275" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11474671" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A synthetic pentasaccharide for the prevention of deep-vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9845387" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Do antiplatelet agents contribute to the development of perioperative spinal hematoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6474093" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10917378" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Warfarin and celecoxib interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315278" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18455116" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Acute spontaneous spinal epidural hematoma: an important differential diagnosis in patients under clopidogrel therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10551621" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Caution in performing epidural injections in patients on several antiplatelet drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12058440" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : [A case of epidural hematoma associated with epidural catheterization which occurred on 12th days after the last medication of ticlopidine hydrochloride].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6869865" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Spinal subarachnoid hematoma after lumbar puncture in a patient receiving antiplatelet therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315266" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315266" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315266" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315266" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315266" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18685937" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Spinal epidural hematoma following epidural catheter removal during antiplatelet therapy with cilostazol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142340" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Case report: continuous interscalene block associated with neck hematoma and postoperative sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22150494" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Large retroperitoneal haematoma: an unexpected complication of ilioinguinal nerve block for inguinal hernia repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655465" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : [ A rare complication of thrombolytic therapy: spinal epidural hematoma. A case report ].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993896" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Spinal epidural hematoma associated with streptokinase treatment for myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12426015" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Spinal epidural hematoma complicating thrombolytic therapy with tissue plasminogen activator--a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15257265" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Spinal epidural hematoma following coronary thrombolysis. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10559822" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Spinal epidural hematoma associated with tissue plasminogen activator treatment of acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1466472" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Epidural hematoma associated with epidural anesthesia: complications of anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2352608" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9633781" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Association of Ginkgo biloba with intracerebral hemorrhage.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
